Reports of rare but serious strokes and tears in the lining of the arteries in the head and neck have occurred in patients with multiple sclerosis (MS) shortly after starting treatment with the drug Lemtrada (alemtuzumab), which can lead to permanent disability and even death, the Food and Drug Administration (FDA) warned in a Safety Communication. The drug ingredient alemtuzumab was initially approved in 2001 under the brand name Campath to treat a type of cancer called B-cell chronic lymphocytic leukemia, or B-CLL. In 2014, the drug was approved under the brand name Lemtrada to treat relapsing forms of MS. ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.